RESUMO
No disponible
Assuntos
Humanos , Masculino , Pessoa de Meia-Idade , Dermatopatias Vesiculobolhosas/diagnóstico , Ectima Contagioso/diagnóstico , Poxviridae/isolamento & purificação , Diagnóstico DiferencialRESUMO
No disponible
Assuntos
Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Técnicas de Diagnóstico Molecular/métodos , Técnicas de Diagnóstico Molecular/tendências , Patologia Molecular/métodos , Diagnóstico Diferencial , Poxviridae/isolamento & purificação , Poxviridae/patogenicidade , Infecções por Poxviridae/diagnóstico , Infecções por Poxviridae , Infecções/complicações , Infecções/diagnóstico , Anamnese/métodos , Anamnese/normas , Antibacterianos/uso terapêuticoRESUMO
El Molluscum contagiosum es una infección viral benigna, causada por un poxvirus, que afecta habitualmente a niños entre 2 y 5 años con tasas de incidencia de entre el 5 y el 8%. Afecta también a individuos adultos sexualmente activos y los pacientes con infección por VIH presentan especial predisposición a esta infección. Generalmente las lesiones son autolimitadas y, aunque se han empleado numerosos tratamientos, no se ha demostrado que ninguna intervención sea más eficaz, por lo que se plantea el debate sobre si las lesiones del molusco contagioso deben ser tratadas o dejar que se resuelvan espontáneamente. Presentamos el caso de un adulto de 21 años con lesiones características y describimos brevemente el diagnóstico y tratamiento de esta infección (AU)
The Molluscum contagiosum is a benign viral infection. It is caused by a poxvirus and usually affects children from 2 to 5 years. The incidence rate is 5-8%. Also affects sexually active adults. Patients with HIV infection presents special predisposition to this infection. Skin lesions are usually self-limited. Although many treatments have been used, no treatment has been proved be more effective than the other. It is unknown whether the skin lesions should be treated or not. We present the case of an adult of 21 years old with characteristic lesions and we brief y describe the diagnosis and treatment of this infection (AU)
Assuntos
Humanos , Masculino , Adulto , Molusco Contagioso/complicações , Molusco Contagioso/diagnóstico , Molusco Contagioso/terapia , Dermatopatias Infecciosas/complicações , Dermatopatias Infecciosas/diagnóstico , Poxviridae/isolamento & purificação , Poxviridae/patogenicidade , Infecções por Poxviridae/complicações , Infecções por Poxviridae/diagnóstico , Diagnóstico Diferencial , Molusco Contagioso/fisiopatologia , Poxviridae , Infecções por Poxviridae/tratamento farmacológico , Infecções por Poxviridae/epidemiologia , Foliculite/complicações , Ceratodermia Palmar e Plantar/complicações , Ceratodermia Palmar e Plantar/diagnósticoRESUMO
Recombinant adenoviruses, poxviruses, and plasmid DNA vaccines encoding different hepatitis B virus (HBV)/murine cytomegalovirus (MCMV) protein chimeras were used to immunize mice. Processing of the chimeras resulted in presentation of a protective Ld/CD8+ T-cell epitope of the immediate early 1 protein pp89 (IE1 pp89) of MCMV to the immune system. Different levels of immunogenicity were observed depending on: (i) the type of viral vector used, (ii) whether the antigens were included in the cellular secretion pathway, and (iii) the location of the protective epitope within the chimeric protein. An adenovirus expressing a secretory HBV core protein with the MCMV epitope in its C-terminus induced the highest immune response. When the most immunogenic adenovirus and vaccinia virus were used in a heterologous prime-boost immunization protocol, even higher levels of epitope-specific T cells were obtained. Furthermore, responses were protective against a challenge with MCMV, inducing up to a 96% reduction of viral load in immunized animals, as determined by a sensitive real-time PCR assay. Together, these results confirmed previous observations of the efficient use of adenoviral and poxviral vectors in prime-boost protocols for immunization against diseases whose resolution depends on cellular immunity, as well as the aptness of correctly designed chimeric carrier proteins to facilitate this goal (AU)
No disponible
